TY - JOUR
T1 - The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters
AU - Aagaard, Kjersti
AU - Petrosino, Joseph
AU - Keitel, Wendy
AU - Watson, Mark
AU - Katancik, James
AU - Garcia, Nathalia
AU - Patel, Shital
AU - Cutting, Mary
AU - Madden, Tessa
AU - Hamilton, Holli
AU - Harris, Emily
AU - Gevers, Dirk
AU - Simone, Gina
AU - McInnes, Pamela
AU - Versalovic, James
PY - 2013/3
Y1 - 2013/3
N2 - The Human Microbiome Project used rigorous good clinical practice standards to complete comprehensive body site sampling in healthy 18- to 40-yr-old adults, creating an unparalleled reference set of microbiome specimens. To ensure that specimens represented minimally perturbed microbiomes, we first screened potential participants using exclusion criteria based on health history, including the presence of systemic diseases (e.g., hypertension, cancer, or immunodeficiency or autoimmune disorders), use of potential immunomodulators, and recent use of antibiotics or probiotics. Subsequent physical examinations excluded individuals based on body mass index (BMI), cutaneous lesions, and oral health. We screened 554 individuals to enroll 300 (149 men and 151 women, mean age 26 yr, mean BMI 24 kg/m2, 20.0% racial minority, and 10.7% Hispanic). We obtained specimens from the oral cavity, nares, skin, gastrointestinal tract, and vagina (15 specimens from men and 18 from women). The study evaluated longitudinal changes in an individual's microbiome by sampling 279 participants twice (mean 212 d after the first sampling; range 30-359 d) and 100 individuals 3 times (mean 72 d after the second sampling; range 30-224 d). This sampling strategy yielded 11,174 primary specimens, from which 12,479 DNA samples were submitted to 4 centers for metagenomic sequencing. Our clinical design and well-defined reference cohort has laid a foundation for microbiome research.
AB - The Human Microbiome Project used rigorous good clinical practice standards to complete comprehensive body site sampling in healthy 18- to 40-yr-old adults, creating an unparalleled reference set of microbiome specimens. To ensure that specimens represented minimally perturbed microbiomes, we first screened potential participants using exclusion criteria based on health history, including the presence of systemic diseases (e.g., hypertension, cancer, or immunodeficiency or autoimmune disorders), use of potential immunomodulators, and recent use of antibiotics or probiotics. Subsequent physical examinations excluded individuals based on body mass index (BMI), cutaneous lesions, and oral health. We screened 554 individuals to enroll 300 (149 men and 151 women, mean age 26 yr, mean BMI 24 kg/m2, 20.0% racial minority, and 10.7% Hispanic). We obtained specimens from the oral cavity, nares, skin, gastrointestinal tract, and vagina (15 specimens from men and 18 from women). The study evaluated longitudinal changes in an individual's microbiome by sampling 279 participants twice (mean 212 d after the first sampling; range 30-359 d) and 100 individuals 3 times (mean 72 d after the second sampling; range 30-224 d). This sampling strategy yielded 11,174 primary specimens, from which 12,479 DNA samples were submitted to 4 centers for metagenomic sequencing. Our clinical design and well-defined reference cohort has laid a foundation for microbiome research.
KW - Clinical metadata
KW - Clinical research studies
KW - HMP clinical data
KW - Metagenomic medicine
KW - Metagenomics
UR - http://www.scopus.com/inward/record.url?scp=84874612821&partnerID=8YFLogxK
U2 - 10.1096/fj.12-220806
DO - 10.1096/fj.12-220806
M3 - Article
C2 - 23165986
AN - SCOPUS:84874612821
SN - 0892-6638
VL - 27
SP - 1012
EP - 1022
JO - FASEB Journal
JF - FASEB Journal
IS - 3
ER -